Elisabetta Orlandini

List of Publications by Year
in descending order

89 papers	1,563 citations	257450 24 h-index	377865 34 g-index
100 all docs	100 docs citations	100 times ranked	2054 citing authors

#	Article	IF	Citations
1	Synthesis and Evaluation of Monoaryl Derivatives as Transthyretin Fibril Formation Inhibitors. Pharmaceutical Chemistry Journal, 2022, 56, 38-47.	0.8	2
2	Nature-Inspired O-Benzyl Oxime-Based Derivatives as New Dual-Acting Agents Targeting Aldose Reductase and Oxidative Stress. Biomolecules, 2022, 12, 448.	4.0	11
3	Antioxidant Quercetin 3-O-Glycosylated Plant Flavonols Contribute to Transthyretin Stabilization. Crystals, 2022, 12, 638.	2.2	3
4	Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 48-57.	5.2	12
5	Application of PROTAC strategy to TTR-Aî² protein-protein interaction for the development of Alzheimerâ€™s disease drugs. Neural Regeneration Research, 2021, 16, 1554.	3.0	10
6	Neuroglobin and neuroprotection: the role of natural and synthetic compounds in neuroglobin pharmacological induction. Neural Regeneration Research, 2021, 16, 2353.	3.0	12
7	Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimerâ€™s Disease. Pharmaceuticals, 2021, 14, 86.	3.8	26
8	Physiological Metals Can Induce Conformational Changes in Transthyretin Structure: Neuroprotection or Misfolding Induction?. Crystals, 2021, 11, 354.	2.2	9
9	Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives. Molecules, 2021, 26, 6380.	3.8	27
10	Multifunctional Small Molecules as Potential Anti-Alzheimerâ€™s Disease Agents. Molecules, 2021, 26, 6015.	3.8	7
11	Novel tacrineâ€“benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimerâ€™s Disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 211-226.	5.2	39
12	Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis. Bioorganic and Medicinal Chemistry, 2020, 28, 115673.	3.0	8
13	Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1145-1162.	5.2	35
14	Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1194-1205.	5.2	5
15	Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration. ACS Chemical Neuroscience, 2020, 11, 3214-3232.	3.5	12
16	Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors. Bioorganic Chemistry, 2019, 92, 103298.	4.1	13
17	Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP). Bioorganic and Medicinal Chemistry, 2019, 27, 196-207.	3.0	9
18	Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement. Current Drug Targets, 2019, 20, 903-918.	2.1	3

#	Article	IF	Citations
19	Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies. Journal of Medicinal Chemistry, 2018, 61, 4421-4435.	6.4	34
20	Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates. Bioorganic and Medicinal Chemistry, 2018, 26, 5804-5815.	3.0	14
21	Copper mediated amyloid-Î² binding to Transthyretin. Scientific Reports, 2018, 8, 13744.	3.3	26
22	Comparison of helical scan and standard rotation methods in single-crystal X-ray data collection strategies. Journal of Synchrotron Radiation, 2017, 24, 42-52.	2.4	27
23	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. ACS Medicinal Chemistry Letters, 2017, 8, 293-298.	2.8	13
24	N -(Aroyl)- N -(arylmethyloxy)-Î±-alanines: Selective inhibitors of aldose reductase. Bioorganic and Medicinal Chemistry, 2017, 25, 3068-3076.	3.0	13
25	Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues. European Journal of Medicinal Chemistry, 2017, 138, 890-899.	5.5	24
26	Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds. ChemMedChem, 2016, 11, 1865-1874.	3.2	16
27	Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR). Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 40-51.	5.2	15
28	Sugarâ€Based Arylsulfonamide Carboxylates as Selective and Waterâ€Soluble Matrix Metalloproteinaseâ€12 Inhibitors. ChemMedChem, 2016, 11, 1626-1637.	3.2	36
29	A new crystal form of human transthyretin obtained with a curcumin derived ligand. Journal of Structural Biology, 2016, 194, 8-17.	2.8	18
30	X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 824-833.	5.2	10
31	Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 406-412.	5.2	6
32	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. Journal of Medicinal Chemistry, 2015, 58, 7224-7240.	6.4	54
33	Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups. Journal of Medicinal Chemistry, 2014, 57, 9152-9167.	6.4	55
34	Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models. Journal of Medicinal Chemistry, 2013, 56, 8089-8103.	6.4	19
35	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 62, 379-394.	5.5	38
36	Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New ¹⁸F-Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission Tomography. Journal of Medicinal Chemistry, 2013, 56, 2676-2689.	6.4	17

#	Article	IF	Citations
37	Tafamidis (Vyndaqel): A Light for FAP Patients. ChemMedChem, 2013, 8, 1617-1619.	3.2	16
38	TTR Fibril Formation Inhibitors: Is there a SAR?. Current Medicinal Chemistry, 2012, 19, 2356-2379.	2.4	25
39	Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit Î±- and Î²-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms. Journal of Medicinal Chemistry, 2012, 55, 9619-9629.	6.4	35
40	A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer. Cellular Signalling, 2012, 24, 951-960.	3.6	16
41	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 825-834.	5.5	15
42	Spirotetrahydronaphthalene analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-3â€² -piperidines]. Journal of Pharmacy and Pharmacology, 2010, 54, 649-660.	2.4	0
43	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Journal of Pharmacy and Pharmacology, 2010, 61, 1057-1066.	2.4	7
44	Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-Î± Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models. Journal of Medicinal Chemistry, 2010, 53, 2622-2635.	6.4	37
45	Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience, 2010, 168, 514-522.	2.3	49
46	Different Binding Modes of Structurally Diverse Ligands for Human D3DAR. Journal of Chemical Information and Modeling, 2010, 50, 2162-2175.	5.4	3
47	Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural Analysis. PLoS ONE, 2009, 4, e6290.	2.5	34
48	N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis. Journal of Medicinal Chemistry, 2009, 52, 4757-4773.	6.4	60
49	Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 6347-6361.	6.4	49
50	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Journal of Pharmacy and Pharmacology, 2009, 61, 1057-1066.	2.4	2
51	Synthesis and 5-HT2A, 5-HT1Aand Î±1-Binding Affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-Hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-Hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) Benzyl Oximes. Archiv Der Pharmazie, 2007, 340, 135-139.	4.1	2
52	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorganic and Medicinal Chemistry, 2007, 15, 2298-2311.	3.0	44
53	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2311-2314.	2.2	23
54	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1321-1326.	2.2	38

#	Article	IF	Citations
55	Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. Il Farmaco, 2004, 59, 25-31.	0.9	33
56	Synthesis and antimicrobial activity of new 7Î²-(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins. Il Farmaco, 2004, 59, 691-696.	0.9	4
57	Synthesis and Prostaglandin Synthase Inhibitory Activity of New Aromatic O-Alkyloxime Ethers Substituted with Methylsulfonamido or Methylsulfonyl Groups on Their Aliphatic Portion.. ChemInform, 2004, 35, no.	0.0	0
58	Synthesis and COX-2 Inhibitory Properties of N-Phenyl- and N-Benzyl-Substituted Amides of 2-(4-Methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic Acid and of Their Pyrazole, Thiophene and Isoxazole Analogues.. ChemInform, 2004, 35, no.	0.0	1
59	New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorganic and Medicinal Chemistry, 2004, 12, 2441-2450.	3.0	79
60	Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion. Il Farmaco, 2003, 58, 707-714.	0.9	3
61	Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring. European Journal of Medicinal Chemistry, 2003, 38, 157-168.	5.5	35
62	NewN-n-Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D4Dopamine Receptor. Journal of Medicinal Chemistry, 2003, 46, 161-168.	6.4	36
63	Conformationally restrained analogues of sympathomimetic catecholamines. European Journal of Medicinal Chemistry, 2002, 37, 11-22.	5.5	4
64	(E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methyliden](arylmethyloxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties. European Journal of Medicinal Chemistry, 2002, 37, 391-398.	5.5	13
65	Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties. European Journal of Medicinal Chemistry, 2002, 37, 585-594.	5.5	6
66	Synthesis and inhibitory activity towards human leukocyte elastase of new 7Î±-methoxy and 7Î±-chloro (2-acyloxymethyl) cephem derivatives. European Journal of Medicinal Chemistry, 2001, 36, 185-193.	5.5	6
67	Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and antiinflammatory properties. European Journal of Medicinal Chemistry, 2001, 36, 799-807.	5.5	8
68	Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 223-226.	2.2	8
69	Synthesis, inhibitory activity towards human leukocyte elastase and molecular modelling studies of 1-carbamoyl-4-methyleneaminoxyazetidinones. European Journal of Medicinal Chemistry, 2000, 35, 53-67.	5.5	15
70	Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues. Il Farmaco, 2000, 55, 104-108.	0.9	5
71	Synthesis and antimicrobial properties of cephalosporin derivatives substituted on the C(7) nitrogen with arylmethyloxyimino or arylmethyloxyamino alkanoyl groups. Il Farmaco, 1999, 54, 224-231.	0.9	6
72	Synthesis and aldose reductase inhibitory activity of new N-(benzyloxy) glycine derivatives. Il Farmaco, 1998, 53, 369-373.	0.9	5

#	Article	IF	Citations
73	Synthesis and Î±-adrenergic and I1-imidazoline activity of 3-phenylpiperidines dimethyl-substituted on the phenyl ring. European Journal of Medicinal Chemistry, 1998, 33, 911-919.	5.5	6
74	N-n-Propyl-Substituted 3-(Dimethylphenyl)piperidines Display Novel Discriminative Properties between Dopamine Receptor Subtypes:Â Synthesis and Receptor Binding Studies1. Journal of Medicinal Chemistry, 1998, 41, 4933-4938.	6.4	12
75	New Î²-lactam monocyclic inhibitors of human elastases: Synthesis and anti-elastase properties of 1-carbamoyl-4-methyleneaminoxyazetidinone derivatives. European Journal of Medicinal Chemistry, 1997, 32, 889-894.	5.5	6
76	Synthesis and Î±-adrenergic activity of 2- and 6-methyl-substituted (3,4-dihydroxyphenyl)-3-piperidinols. European Journal of Medicinal Chemistry, 1997, 32, 231-240.	5.5	10
77	Synthesis and antimicrobial activity of 7 beta-(S)- and 7 beta-[(R)-3-(methyleneaminoxy)-2-methylpropionamido]substituted cephalosporanic acid derivatives. Il Farmaco, 1996, 51, 283-6.	0.9	2
78	Role of the benzylic hydroxyl group of adrenergic catecholamines in eliciting Î±-adrenergic activity. Synthesis and Î±1- and Î±2-adrenergic activity of 3-phenyl-3-piperidinols and their desoxy analogs. European Journal of Medicinal Chemistry, 1995, 30, 869-880.	5.5	9
79	Synthesis and adrenergic beta-blocking activity of ortho-, meta- and para-oxypropanolamino-substituted [(benzylideneamino)oxy]propanolamines. Il Farmaco, 1995, 50, 239-43.	0.9	2
80	Synthesis and antimicrobial activity of 7 beta-[N-(arylmethyloxyimino) acetamido]cephalosporanic acid derivatives. Il Farmaco, 1995, 50, 713-8.	0.9	6
81	Conformationally restrained Î²-blocking oxime ethers. 2. Synthesis and Î²-adrenergic properties of diastereoisomeric anti and syn 2-(5â€²-(3â€²-aryl-substituted)isoxazolidinyl)-N-alkylethanolaminesâ€ . European Journal of Medicinal Chemistry, 1994, 29, 855-867.	5.5	7
82	Synthesis, antiinflammatory activity and molecular orbital studies of a series of benzylideneaminoxypropionic acids substituted on the phenyl ring. European Journal of Medicinal Chemistry, 1994, 29, 33-39.	5.5	11
83	Synthesis and aldose reductase inhibitory activity of N-(arylsulfonyl)- and N-(aroyl)-N-(arylmethyloxy)glycines. European Journal of Medicinal Chemistry, 1994, 29, 787-794.	5.5	17
84	SynthÃ¨ses et propriÃ©tÃ©s antimicrobiennes de (E)-3-aminoxy-2-mÃ©thoxyimino propionyl pÃ©nicillines et cÃ©phalosporines. European Journal of Medicinal Chemistry, 1990, 25, 227-233.	5.5	21
85	Molecular design, synthesis, and antiinflammatory activity of a series of .beta.-aminoxypropionic acids. Journal of Medicinal Chemistry, 1990, 33, 1423-1430.	6.4	22
86	Synthesis and antimicrobial properties of substituted 3-aminoxypropionyl and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams. Il Farmaco, 1990, 45, 879-88.	0.9	3
87	SynthÃ¨se et propriÃ©tÃ©s anti-microbiennes des nouveaux dÃ©rivÃ©s cÃ©phame et pÃ©name avec le groupe carboxylique dans la â€œmauvaiseâ€•configuration Î². European Journal of Medicinal Chemistry, 1989, 24, 573-577.	5.5	1
88	Synthesis and antimicrobial properties of substituted .beta.-aminoxypropionyl penicillins and cephalosporins. Journal of Medicinal Chemistry, 1989, 32, 1398-1401.	6.4	20
89	Synthesis and evaluation of the pharmacological activity of rigid analogs of sympathomimetic catecholamines derived from bicyclo[2.2.1]heptane. Journal of Medicinal Chemistry, 1989, 32, 856-859.	6.4	8